251 active trials 134 recruiting 22 Phase 3 29 disease areas 7 changes in 30 days
4 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 3 with minor changes only.
Enrollment reopened
Also in this update: Primary completion pushed from Jul 1, 2026 to Dec 1, 2026
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 NCT06342167 Registry history of NCT06342167 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Final enrollment: 20 participants (planned 60); Primary completion date changed from estimate of Mar 2025 to Dec 9, 2023
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1 NCT05392699 Registry history of NCT05392699 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Jun 30, 2026 to Sep 1, 2026
Cancer Institute and Hospital, Chinese Academy of Medical SciencesNot specified NCT07429318 Registry history of NCT07429318 on ClinicalTrials.gov (opens the registry)
Updated
Registry marked status Unknown (sponsor has not verified the record since Apr 2024); last known: Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1/2 NCT06202001 Registry history of NCT06202001 on ClinicalTrials.gov (opens the registry)
Changed
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-08 | NCT07865793 Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1… | Phase 2 | Recruiting |
| 2026-10-07 | NCT07863869 The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially… | Phase 1/2 | Not Yet Recruiting |
| 2026-10-05 | NCT07858630 Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the… | Recruiting | |
| 2026-10-05 | NCT07859462 Phase I Study of In Vivo CAR-Tumor Technology for the Treatment of Advanced Malignant… | Phase 1 | Not Yet Recruiting |
| 2026-09-25 | NCT07842887 Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation… | Phase 1 | Not Yet Recruiting |
| 2026-09-22 | NCT07835035 Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard… | Phase 1 | Recruiting |
| 2026-09-15 | NCT07819669 Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS… | Not Yet Recruiting |
| Early Phase 1 | 14 | |
| Phase 1 | 16 | |
| Phase 1/2 | 12 | |
| Phase 2 | 103 | |
| Phase 2/3 | 3 | |
| Phase 3 | 19 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or… | Breast Cancer | Not Yet Recruiting | 2024-02-07 |
| Phase 3 | ||||
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC | Small-cell Lung Cancer | Recruiting | 2026-10-08 |
| NCT07692152 | Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage… | Anal Squamous Cell Carcinoma, Limited-stage | Recruiting | 2026-07-09 |
| NCT07084519 | Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction | Breast Cancer | Recruiting | 2026-06-22 |
| NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma (NPC) | Recruiting | 2026-06-04 |
| NCT07443397 | Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. | Whole-Brain Radiotherapy | Recruiting | 2026-03-02 |
| NCT07383246 | CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC | Medullary Thyroid Carcinoma | Recruiting | 2026-02-03 |
| NCT04821778 | Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer | Esophagus Cancer | Recruiting | 2026-01-21 |
| NCT04821843 | Neoadjuvant Treatment Modalities in Esophageal Cancer | Esophageal Cancer | Recruiting | 2026-01-21 |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | Hepatocellular Carcinoma (HCC) | Recruiting | 2025-09-22 |
| NCT06757621 | Hypofractionated Postoperative Regional Nodal Irradiation for Patients With… | Breast Carcinoma | Recruiting | 2025-01-03 |
| NCT06086457 | PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic… | Esophageal Neoplasms | Recruiting | 2024-07-16 |
| NCT06082180 | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of… | Thyroid Cancer | Recruiting | 2023-10-13 |
| NCT07586657 | Precision Radiotherapy for Refractory Brain Metastases: A Multicenter Study | Brain Metastasases | Not Yet Recruiting | 2026-05-14 |
| NCT07560358 | Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III… | NSCLC (Advanced Non-small Cell Lung Cancer) | Not Yet Recruiting | 2026-05-01 |
| NCT07385365 | A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer | Breast Cancer | Not Yet Recruiting | 2026-02-11 |
| NCT04320979 | Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients | Breast Cancer | Active, Not Recruiting | 2026-01-13 |
| NCT07239271 | A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant… | Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy | Not Yet Recruiting | 2025-11-20 |
| NCT06837597 | Jianzhong Qushi in Chronic RRI | Chronic Radiation Proctitis | Not Yet Recruiting | 2025-02-27 |
| NCT06149533 | Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis… | Thrombosis, Venous | Not Yet Recruiting | 2023-11-29 |
| Phase 2/3 | ||||
| NCT05749289 | Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression | SSTR Positive Tumors | Recruiting | 2026-04-06 |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib… | HER2 Positive Breast Cancer | Recruiting | 2025-05-06 |
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and… | Triple-Negative Breast Cancer (TNBC) | Enrolling by Invitation | 2026-08-18 |
| Phase 2 | ||||
| NCT07865793 | Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1… | Advanced Malignant Solid Tumor | Recruiting | 2026-10-08 |
| NCT06342167 | Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition… | Locally Advanced Esophageal Squamous Cell Carcinoma | Recruiting | 2026-10-07 |
Breast Cancer (42) · Lung Cancer (30) · Non-Small Cell Lung Cancer (NSCLC) (25) · Esophageal Cancer (21) · Colorectal Cancer (19) · Head & Neck Cancer (12) · Small Cell Lung Cancer (8) · Cervical Cancer (7) · Liver Cancer (7) · Bladder Cancer (6)